Community Forum top_calendar.gif top_members.gif top_faq.gif top_search.gif top_home.gif    

Go Back   Community Forum > The Internet Medical Journal > News
User Name
Password
FAQ Members List Calendar Search Today's Posts Mark Forums Read


Reply
 
Thread Tools Search this Thread Display Modes
  #1  
Old June 13th, 2005, 21:27
sysadmin sysadmin is offline
Administrator
 
Join Date: 2001
Posts: 1,085
Dobutamine stress tetrofosmin SPECT vs MIBI

OBJECTIVE: to compare the performance of tetrofosmin compared to sestamibi in myocardial perfusion SPECT imaging. METHODS: 19 patients with known coronary artery disease were studied. All patients initially underwent perfusion rest-stress SPECT imaging with sestamibi. Dobutamine stress was used in all patients. A week later, all patients underwent tetrofosmin SPECT imaging. Results were compared with findings on angiography. The time from injection to imaging was 60 minutes for the sestamibi study, and 30 minutes for the tetrofosmin study. RESULTS: When comparing sestamibi versus tetrofosmin, there was no significant differences in the heart-to-liver or heart-to-lung ratios. A head-to-head segmental analysis showed good correlation between sestamibi and tetrofosmin tracers. The overall accuracy of each tracer, compared with angiographic findings, was statistically identical, at 84% for sestamibi and 82% for tetrofosmin. Furthermore, tetrofosmin showed a better reversibility degree (55%) in a shorter time when compared to sestamibi (25%) in perfusion defects, especially in segments with severely decreased perfusion or no uptake. CONCLUSION: tetrofosmin and sestamibi have a similar diagnostic performance. Tetrofosmin has the advantage in that imaging can begin at 30 minutes after injection, compared to 60 minutes after injection for sestamibi. PMID: 15909491

Ann Nucl Med. 2005 Apr;19(2):115-22. Related Articles, Links


Dobutamine stress tetrofosmin SPECT; evaluation of short rest-stress protocol and head to head comparison with MIBI in detection of coronary artery disease.

Turgut B, Unlu M, Cengel A.

Department of Nuclear Medicine, Cumhuriyet University School of Medicine, Sivas, Turkey. bturgut@cumhuriyet.edu.tr


http://www.ncbi.nlm.nih.gov/entrez/...9491&query_hl=1

ncupdate 2005
Reply With Quote
Reply


Thread Tools Search this Thread
Search this Thread:

Advanced Search
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is On
Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
Noninvasive assessment of coronary microvascular dysfunction using Tc-99m tetrofosmin sysadmin News 0 May 9th, 2005 07:32
Prognostic value of stress Tc-99m tetrofosmin SPECT in patients with previous MI sysadmin News 0 December 20th, 2004 07:07
American Society of Nuclear Medicine Announces Annual Meeting Poster Presentations anonymous News 0 June 4th, 2004 21:01
Long-Term Prognosis After a Normal Exercise Stress Tc-99m Sestamibi SPECT Study sysadmin Long-Term Prognosis After a Normal Exercise Sestamibi SPECT Scan 0 November 18th, 2003 19:20
2002.10.01 Nuclear Medicine News sysadmin News 0 February 16th, 2003 11:45


All times are GMT -8. The time now is 09:09.


Powered by: vBulletin Version 3.0.3
Copyright ©2000 - 2018, Jelsoft Enterprises Ltd.



Be careful about reading health books. You may die of a misprint.  
- Mark Twain (1835 - 1910)

We are committed to your good health. That means that while we provide editorial medical information, we must insist that you work with your own doctor in regards to your personal health issues. All content on Medjournal.Com is strictly editorial. It constitutes medical opinion, NOT ADVICE. We do not endorse or recommend the content of Medjournal.com or the sites that are linked FROM or TO Medjournal.com. Use common sense by consulting with your doctor before making any lifestyle changes or other medical decisions based on the content of these web pages. Medjournal.Com and the Internet Medical Journal shall not be held liable for any errors in content, advertising, or for any actions taken in reliance thereon.